Israeli Wound Management Company Red dress Today I announce the completion of a $26 million Series D funding round with participation from ATHOS Biopharma GmbH and other life sciences investors including HCS Capital Investors Group and Ragnar Crossover Fund. The latest investment round brings the total amount raised by RedDress to $43 million.
RedDress has developed a personalized and self-contained wound management solution created from patients’ blood. The new funds will be used to fuel increased adoption of the company’s product, create global partnerships, and expand RedDress’s blood-based technology to treat more conditions.
RedDress has pioneered the use of blood-based technology to treat chronic wounds that have virtually no risk of rejection and are more cost-effective. The ActiGraft family of products is an autologous, point-of-care wound management solution that produces, in real time, a blood clot in the laboratory from patients’ whole blood. Once a blood clot is applied to a wound, the wound healing process begins, acts as a protective covering, and improves the body’s ability to heal. The ActiGraft family of products can be used for a variety of chronic wounds including diabetic and neuropathic ulcers, venous ulcers, pressure injuries, traumatic wounds, postoperative wounds, skin lacerations, surgical wounds and more.
RedDress Founder and CEO, Alon Kushner, said, “Healing is in our blood, and we are grateful for the continued support from our investors as we advance our mission of providing healthcare providers with an effective solution for treating chronic and complex wounds through an innovative system that harnesses the power of a patient’s blood.” The funding round confirms. This latest efficacy and strong market performance of the ActiGraft system provides us with important resources to expand blood-based autologous wound care solutions so that we can continue to develop new innovations in other areas of healthcare.”
Since RedDress received FDA authorization and CE marking in 2020, ActiGraft has helped more than 6,000 patients in the United States and 30 other countries.
Published by Globes, Israel business news – en.globes.co.il – on May 24, 2023.
© Copyright Globes Publisher Itonut (1983) Ltd., 2023.
